No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	decitabine/cedazuridine Sensitive: A1 - Approval Otsuka Press Release - 2 weeks (New A1) decitabine / cedazuridine Sensitive : A1 Otsuka Press Release - 2wk	decitabine/cedazuridine Sensitive: A1 - Approval Otsuka Press Release - 2 weeks decitabine / cedazuridine Sensitive : A1 Otsuka Press Release - 2 weeks - (New A1)
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	quizartinib Sensitive: A1 - Approval Daiichi Sankyo Press Release - 2 weeks (New B) quizartinib Sensitive : A1 Daiichi Sankyo Press Release - 2wk	quizartinib Sensitive: A1 - Approval Daiichi Sankyo Press Release - 2 weeks quizartinib Sensitive : A1 Daiichi Sankyo Press Release - 2 weeks - (New B)
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	GS-4721 Sensitive: C2 – Inclusion Criteria J Clin Oncol - 2 weeks (New C3) GS-4721 Sensitive : C2 J Clin Oncol - 2wk	GS-4721 Sensitive: C2 – Inclusion Criteria J Clin Oncol - 2 weeks GS-4721 Sensitive : C2 J Clin Oncol - 2 weeks - (New C3)
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	DCP-001 Sensitive: B - Late Trials GlobeNewswire - 3 weeks (New B) DCP-001 Sensitive : B GlobeNewswire - 3wk	DCP-001 Sensitive: B - Late Trials GlobeNewswire - 3 weeks DCP-001 Sensitive : B GlobeNewswire - 3 weeks - (New B)
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: A1 - Approval gilteritinib Sensitive : A1	gilteritinib Sensitive: A1 - Approval gilteritinib Sensitive : A1
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	enasidenib Sensitive: A1 - Approval enasidenib Sensitive : A1	enasidenib Sensitive: A1 - Approval enasidenib Sensitive : A1
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	glasdegib Sensitive: A1 - Approval glasdegib Sensitive : A1	glasdegib Sensitive: A1 - Approval glasdegib Sensitive : A1
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	azacitidine oral Sensitive: A1 - Approval azacitidine oral Sensitive : A1	azacitidine oral Sensitive: A1 - Approval azacitidine oral Sensitive : A1
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: A1 - Approval cytarabine / daunorubicin liposomal formulation Sensitive : A1	cytarabine/daunorubicin liposomal formulation Sensitive: A1 - Approval cytarabine / daunorubicin liposomal formulation Sensitive : A1
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	midostaurin Sensitive: A1 - Approval midostaurin Sensitive : A1	midostaurin Sensitive: A1 - Approval midostaurin Sensitive : A1
CD33 positive	Acute Myelogenous Leukemia	CD33 positive	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: A1 - Approval gemtuzumab ozogamicin Sensitive : A1	gemtuzumab ozogamicin Sensitive: A1 - Approval gemtuzumab ozogamicin Sensitive : A1
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	olutasidenib Sensitive: A1 - Approval olutasidenib Sensitive : A1	olutasidenib Sensitive: A1 - Approval olutasidenib Sensitive : A1
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	venetoclax Sensitive: A1 - Approval venetoclax Sensitive : A1	venetoclax Sensitive: A1 - Approval venetoclax Sensitive : A1
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	decitabine Sensitive: A1 - Approval decitabine Sensitive : A1	decitabine Sensitive: A1 - Approval decitabine Sensitive : A1
Chr t(15;17)	Acute Promyelocytic Leukemia	Chr t(15;17)	Acute Promyelocytic Leukemia	arsenic trioxide Sensitive: A1 - Approval arsenic trioxide Sensitive : A1	arsenic trioxide Sensitive: A1 - Approval arsenic trioxide Sensitive : A1
PML-RARA fusion	Acute Promyelocytic Leukemia	PML-RARA fusion	Acute Promyelocytic Leukemia	arsenic trioxide Sensitive: A1 - Approval arsenic trioxide Sensitive : A1	arsenic trioxide Sensitive: A1 - Approval arsenic trioxide Sensitive : A1
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	azacitidine Sensitive: A1 - Approval azacitidine Sensitive : A1	azacitidine Sensitive: A1 - Approval azacitidine Sensitive : A1
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	idarubicin hydrochloride Sensitive: A1 - Approval idarubicin hydrochloride Sensitive : A1	idarubicin hydrochloride Sensitive: A1 - Approval idarubicin hydrochloride Sensitive : A1
IDH1 R132	Acute Myelogenous Leukemia	IDH1 R132	Acute Myelogenous Leukemia	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	midostaurin Sensitive: A2 - Guideline midostaurin Sensitive : A2	midostaurin Sensitive: A2 - Guideline midostaurin Sensitive : A2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	midostaurin Sensitive: A2 - Guideline midostaurin Sensitive : A2	midostaurin Sensitive: A2 - Guideline midostaurin Sensitive : A2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: A2 - Guideline gilteritinib Sensitive : A2	gilteritinib Sensitive: A2 - Guideline gilteritinib Sensitive : A2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	cytarabine Sensitive: A2 - Guideline cytarabine Sensitive : A2	cytarabine Sensitive: A2 - Guideline cytarabine Sensitive : A2
RUNX1-RUNX1T1 fusion	Acute Myelogenous Leukemia	RUNX1-RUNX1T1 fusion	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2
CBFB-MYH11 fusion	Acute Myelogenous Leukemia	CBFB-MYH11 fusion	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: A2 - Guideline gilteritinib Sensitive : A2	gilteritinib Sensitive: A2 - Guideline gilteritinib Sensitive : A2
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	cytarabine + fludarabine IV + GCSF Sensitive: A2 - Guideline cytarabine + fludarabine IV + GCSF Sensitive : A2	cytarabine + fludarabine IV + GCSF Sensitive: A2 - Guideline cytarabine + fludarabine IV + GCSF Sensitive : A2
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	cytarabine + idarubicin hydrochloride + fludarabine IV + GCSF Sensitive: A2 - Guideline cytarabine + idarubicin hydrochloride + fludarabine IV + GCSF Sensitive : A2	cytarabine + idarubicin hydrochloride + fludarabine IV + GCSF Sensitive: A2 - Guideline cytarabine + idarubicin hydrochloride + fludarabine IV + GCSF Sensitive : A2
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2
No biomarker	Acute Promyelocytic Leukemia	No biomarker	Acute Promyelocytic Leukemia	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2

Acute Myelogenous Leukemia

Associations(948)

Associations
(948)